Audit: QRS - Zinc-L-Carnosine for Health & Longevity

Audit conducted on 12/09/2026 05:56 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All doses (150 mg/day, 34 mg elemental zinc, 116 mg L-carnosine; 75 mg/day, 17 mg elemental zinc), time windows (1–2 weeks, 4–8 weeks, 14 days), biomarker ranges and gate items trace to ER lines 326–348, 370–388, 435 and 463–480.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“reasonably firm evidence” and “the picture thins” mirror ER Conclusion lines 504–506 verbatim in register.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Penicillamine/trientine kept as a contraindication (ER line 328 “Absolute contraindication”); PPIs/H2 blockers kept as “monitor” (ER line 332).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Gates draw only from ER Key Interactions & Contraindications; benefits/risks only from the respective tiered ER sections. No modifying-factor content migrated.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, NCT IDs, author names or brand names (PepZin GI, Promac, Zeria, Hamari) appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Sober, narrow-claim framing of the ER Conclusion is carried through, including the “beyond that the picture thins” qualification.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Protocol, time-to-effect, monitoring and cadence give an actionable frame while the evidence limits stay explicit.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Items are stated as facts and decision gates, not as instructions issued to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No “should”, “we recommend”, or prescriptive second-person constructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	Gate and protocol cells state facts and separations; the only imperative, “monitor”, is the ER’s own label (line 332).
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No occurrence of “you”, “your” or “yours” in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Plain glosses retained where the ER used them (“bone-density medications”, “medications that cut stomach acid”, “filtration rate”).
2.8	Information is presented in a concise and very compact manner	🟢	Gate items are single clauses; benefit/risk tiers are semicolon-separated phrases; qualitative items are trimmed to the core phrase.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no second-person pronouns anywhere in the document.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Copper-displacement hazard, the 40 mg elemental-zinc ceiling and a seven-marker panel are surfaced for a risk-aware reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Split twice-daily dosing, multi-hour separations from six drug/mineral classes and repeat laboratory monitoring are all presented without dilution.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “ask your doctor” framing; biomarker targets and ratios are given numerically.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-a-glance places the narrow local-mucosal benefit against the sustained-zinc copper hazard, which is the distinction that matters for continuous supplement users.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” string present; the title uses the ER’s “for Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	Lede uses “prescription medication”, “supplement”; no lay route-of-administration phrasing (“pill”, “taken by mouth”) anywhere.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim at lines 446, 492, 534, 569, 590, 633, 659, 663–665, 775 and in the four tier labels of both tiered cards.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Full set matched; marker_#* expanded to marker_1..7 and qualitative_item# to qualitative_item_1..6.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Head/CSS block is byte-identical to the template except the page_title substitution; footer block, website="evidence_review", website="audit" and website="full_review" spans are unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section relied on by the QRS is empty.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard Japanese regimen”, “Supplement-sector regimen”, “Dosing with food” (ER 370, 372, 388) and all seven interaction labels carry the ER’s bold label text.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Protocol and interaction labels are the ER’s own; monitoring row labels match the ER table column 1 exactly. Time-to-effect sub-labels are derived from the single ER “Time to effect” bullet, as the template requires.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji present; the ER’s “⚠️ Conflicted” marker on the oral-mucositis benefit was correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	No sections or rows added beyond the template; every over-long ER bullet was condensed in place (drug lists trimmed, qualitative bullets cut to the core phrase, cadence compressed to two sentences).

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after the doctype and before the template comment at line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at line 3, closing “—” at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no metadata value is repeated in the header, footer or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, and it contains a colon requiring YAML quoting.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: zinc_l_carnosine_2026-0912-0323_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.11, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0912-0511.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the on-disk filename zinc_l_carnosine_2026-0912-0323_Opus_QRS.html.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Zinc-L-Carnosine for Health & Longevity - Quick Reference Sheet”, matching ER frontmatter line 8 with & encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Zinc-L-Carnosine for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: 09/12/2026, correctly derived from 2026-0912-0511.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header contains only the title and the unmodified template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses ER lines 504–510: what it is, what it does locally, the three firm claims, the thinning beyond, and the copper hazard.
7.2	[at_a_glance] is no longer than 60 words	🟢	59 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Prescription/supplement status ER 38; local adhesion and the three firm claims ER 504; “picture thins” ER 506; copper displacement ER 510.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“ulcer-causing bacterium” replaces Helicobacter pylori; no acronyms, no clinical-register terms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial names, years, sample sizes or p-values.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No odds ratios, confidence intervals or percentages.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items trace to ER lines 328 and 344–348.
8.2	[stop_items] represent the Contraindications from the ER	🟢	The five “Populations who should avoid” entries plus the penicillamine/trientine absolute contraindication (ER line 328) — complete.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the span at lines 571–586.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	No dashes and no rationale; the ER’s EFSA justification for pregnancy/lactation and the dialysis-accumulation rationale for CKD were both stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	The eGFR threshold is preserved and shortened to “(filtration rate below 30 mL/min/1.73 m²)”; “until copper status is corrected”, “on prescribed chelation” and the two supervision qualifiers are all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER does identify such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items trace to ER lines 326–340.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s eight interaction bullets; penicillamine/trientine correctly excluded because it sits in [stop_items].
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the span at lines 592–624.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Each item reduced to effect plus separation window; the ER’s chelation, transporter-competition and “does not protect kidney or heart” rationales are all stripped. No dashes used.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists retained and trimmed rather than dropped (doxycycline/ciprofloxacin; alendronate; omeprazole/famotidine; calcium carbonate/ibuprofen); the plain-language glosses and the 2-hour, 4–6 hour, 1–2 mg and 40 mg values are preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells trace to the ER Therapeutic Protocol bullets at lines 370, 372 and 388.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The two headline regimens (licensed 150 mg/day; supplement-sector 75 mg/day) plus administration relative to meals — the three aspects that determine what is actually taken and how.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER Therapeutic Protocol section contains far more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated; elemental-zinc figures (34 mg, 17 mg), the L-carnosine figure (116 mg) and the phytate caveat all come from ER lines 370, 372 and 388.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Symptom relief, endoscopic healing and the gut-permeability effect — exactly the three aspects in the ER “Time to effect” bullet at line 435.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	The two ulcer-healing endpoints (High-tier benefit) precede the gut-permeability endpoint (Medium-tier benefit).
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	1–2 weeks, 4–8 weeks and 14 days with their trial contexts, all from ER line 435.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information; the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All fourteen items map one-to-one onto the ER benefit headings at lines 152–236.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated at lines 536–562.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER heading text; every Magnitude: line (90.3% healing, OR 2.01, 9.08 µg/dL, OR 0.48, etc.) is excluded.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	ER parentheticals such as “(ESD — removal of an early gastric tumour through an endoscope)” and “(confusion and impaired thinking caused by advanced liver disease)” do not appear.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER, so no span needed hiding.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All seven items map one-to-one onto the ER risk headings at lines 262–304.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated at lines 635–653.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Reduced to the ER heading text; the 0.0%/2.1%/14.9% incidence figures, the 37-case series and the EFSA particle-characterisation reasoning are all excluded.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	The ER’s “(a bone-marrow disorder)” gloss and all incidence figures are absent.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four tiers contain items in the ER, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table rows reproduce the ER Monitoring Protocol & Defining Success biomarker table at lines 463–471.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All seven ER rows present with matching ranges: serum zinc 80–120 µg/dL, serum copper 90–130 µg/dL, ceruloplasmin 25–45 mg/dL, zinc-to-copper ratio 0.7–1.0, full blood count with differential, alkaline phosphatase 70–100 IU/L, faecal calprotectin below 50 µg/g.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 764–769 condense ER line 461: baseline, serum zinc at four weeks, copper/ceruloplasmin/blood count at three months then six-monthly, endoscopic reassessment at four to eight weeks.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All six items trace to the ER qualitative-marker list at lines 475–480.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	Complete six-for-six: upper-abdominal symptoms, belching/nausea/distension, taste acuity, appetite and food intake, energy and exercise tolerance, and the neurological copper-depletion warning signs.

Issues 12/09/2026 05:56

Pass rate 100.00%. No issues found.

Issues 12/09/2026 05:49

1. 2.5 — Imperative phrasing in Key Interactions: The [caution_items] gate issues instructions rather than presenting information — “separate by 2 hours before or 4–6 hours after” (line 596), “separate by 2 hours” (lines 600 and 618) and “separate antacids by 2 hours” (line 610) — where the ER states the same facts descriptively (“Separation of at least two hours before or four to six hours after the antibiotic is the usual mitigation”, ER line 326).

Fixes 12/09/2026 05:49

1. 2.5 — Imperative phrasing in Key Interactions: Converted the four directive clauses in [caution_items] to descriptive noun phrases — “separate by 2 hours before or 4–6 hours after” to “2-hour separation before or 4–6 hours after”, “separate by 2 hours” to “2-hour separation” (bisphosphonates and iron/calcium), and “separate antacids by 2 hours” to “2-hour separation from antacids”.

Issues 12/09/2026 05:42

1. 1.3 — Mucositis benefit overstated: Line 552 renders the ER benefit “Reduced Severity of Chemoradiotherapy-Induced Oral Mucositis” (ER line 192) as “Reduced chemoradiotherapy-induced oral mucositis”, which reads as reduced incidence rather than reduced severity — the ER’s magnitude applies only to grade 3 or worse mucositis.
2. 9.4 — Mechanistic rationale in interactions: Line 610 keeps “antacids bind zinc”, a mechanistic rationale redundant with the item’s own label, and line 605 keeps the elaboration “co-use established, not prohibited” after the operative word “monitor”.
3. 1.1 — Verbless zinc-stacking item: Line 622 reads “total elemental zinc past the 40 mg daily limit”, a fragment with no verb that asserts nothing; the ER (line 340) states that stacking other zinc products pushes total elemental zinc past the 40 mg daily upper limit.

Fixes 12/09/2026 05:42

1. 1.3 — Mucositis benefit severity restored: Changed the Low-tier benefit from “Reduced chemoradiotherapy-induced oral mucositis” to “Reduced severity of chemoradiotherapy-induced oral mucositis”, matching the ER heading.
2. 9.4 — PPI elaboration stripped: Trimmed the proton pump inhibitor / H2 blocker item from “monitor; co-use established, not prohibited” to just “monitor”.
3. 9.4 — Antacid mechanism removed: Replaced “antacids bind zinc; separate by 2 hours” with “separate antacids by 2 hours”, dropping the mechanistic rationale redundant with the item label.
4. 1.1 — Zinc-stacking item given a verb: Changed “total elemental zinc past the 40 mg daily limit” to “push total elemental zinc past the 40 mg daily limit”, restoring the ER’s assertion.

Issues 12/09/2026 05:34

1. 4.2 / 4.3 — PPI label gloss paraphrased: The ER bold label at line 332 reads “Proton pump inhibitors and H2 blockers (medications that cut stomach acid; omeprazole, esomeprazole, famotidine)”, but the QRS Key Interactions item (lines 603-604) rewrites the parenthetical gloss as “acid-suppressing medications” rather than carrying the ER wording or trimming it by deletion, as every other interaction label does.

Fixes 12/09/2026 05:34

1. 4.2 / 4.3 — PPI label gloss restored: Changed the Key Interactions parenthetical gloss from “acid-suppressing medications” back to the ER’s verbatim wording “medications that cut stomach acid”, keeping the trimmed example-drug list.

Issues 12/09/2026 05:27

1. 4.5 — One-page budget exceeded: Rendered content runs to roughly 1.8 A4 pages at the template’s 11pt/9.5pt metrics; the main excesses are [caution_items] at 922 characters inside a half-width gate column (lines 594–624), the six qualitative items carrying the ER’s trailing explanatory clauses verbatim (lines 782–815), and the three [time_#_sub] cells that only restate their own label and value (lines 504, 515, 526).

Fixes 12/09/2026 05:27

1. 4.5 — Key Interactions condensed: Trimmed the parenthetical example-drug lists to two named agents each (all lists preserved, none dropped) and tightened every mitigation clause (“separation of at least two hours” → “separate by 2 hours”), cutting [caution_items] from 922 to 748 characters in the half-width gate column.
2. 4.5 — Qualitative items stripped of trailing clauses: Removed the ER’s explanatory tails carried over verbatim (e.g., “the endpoint that matters most in chemotherapy-related taste disturbance”, “before blood counts fall”), reducing the six items from 587 to 349 characters while keeping all six markers and the copper-depletion framing.
3. 4.5 — Time-to-effect subs de-duplicated: Replaced the three [time_#_sub] cells that merely restated their own label and value with short provenance notes (“Reported in ulcer trials.”, “Assessed endoscopically in ulcer trials.”, “Reached full size after 14 days of dosing.”), dropping the row from two rendered lines to one.
4. 4.5 — Protocol, Benefits, Monitoring tightened: Condensed [action_1_sub] and [action_3_sub], shortened [benefits_low] to its bare benefit list, compressed [monitoring_cadence], and trimmed [marker_5_target], [marker_5_why], [marker_6_why] and [marker_7_why]. Total rendered text fell from 5,691 to 4,956 characters with no variable, list item or biomarker row removed.

Issues 12/09/2026 05:19

1. 1.4 — Protocol cell 3 sub mismatched to label: The third Protocol cell carries the ER bold label “Dosing with food” and the value “With or just after meals”, but [action_3_sub] (QRS lines 484-487) presents facts lifted from two other ER bullets — “Splitting is used in every published trial; the evening dose commonly follows the last meal” — so the supporting text does not belong to the labelled fact.
2. 2.5 — Imperative mitigations in Key Interactions: [caution_items] (QRS lines 594-624) render the ER’s descriptive mitigations as bare imperatives — “separate by at least two hours before or four to six hours after” (line 597), “separate by at least two hours” (lines 601, 619), “antacids bind zinc, separate by two hours” (line 611) — where the ER states them descriptively (“Separation of at least two hours … is the usual mitigation”, ER line 326).

Fixes 12/09/2026 05:19

1. 1.4 — Protocol cell 3 sub realigned: Replaced [action_3_sub] (“Splitting is used in every published trial; the evening dose commonly follows the last meal.”) with the ER’s own rationale for the labelled fact: “Food slows gastric emptying and extends mucosal contact while reducing irritation, at some cost to zinc absorption from meals rich in phytate.”
2. 2.5 — Imperatives in Key Interactions removed: Converted the four reader-directed imperatives in [caution_items] to the ER’s descriptive noun phrasing — “separate by at least two hours before or four to six hours after” → “separation of at least two hours before or four to six hours after”, “separate by at least two hours” → “separation of at least two hours” (twice), and “antacids bind zinc, separate by two hours” → “antacids bind zinc; separation of two hours”.